ASHP Continues to Rapidly Update Assessment of Evidence for COVID-19-Related Treatments

ASHP continues to rapidly update their COVID-19 resource center. On the website, you can find information related to leadership, pharmacy workforce, patient care, policy and advocacy and infection prevention. This is also a COVID-19 connect community for pharmacists to post and reply to questions from the field.

One of the most active and fluid resources is the “Assessment of Evidence for COVID-19 Related Treatments.” ASHP has been updating this extremely valuable resource every few days as additional evidence is discovered.

The drugs are categorized by antiviral agents, supporting agents, and other. The evidence table contains the drug, AHFS class, usage rationale, dosage information, and additional comments from ASHP. This is an extremely important resource as data rapidly changes day to day.

The information contained in this evidence table is emerging and rapidly evolving because of ongoing research and is subject to the professional judgment and interpretation of the practitioner due to the uniqueness of each medical facility’s approach to the care of patients with COVID-19 and the needs of individual patients. 

ASHP provides this evidence table to help practitioners better understand current approaches related to treatment and care. ASHP has made reasonable efforts to ensure the accuracy and appropriateness of the information presented.

However, any reader of this information is advised ASHP is not responsible for the continued currency of the information, for any errors or omissions, and/or for any consequences arising from the use of the information in the evidence table in any and all practice settings.

Any reader of this document is cautioned that ASHP makes no representation, guarantee, or warranty, express or implied, as to the accuracy and appropriateness of the information contained in this evidence table and will bear no responsibility or liability for the results or consequences of its use.

OTHER BLOGS YOU MIGHT BE INTERESTED IN... 

• Interlock Pass-thru Pharmacy Refrigerators for Your USP <797> Clean Room
• Remote Access Control – Using 3rd Party Validation Systems to Control Access to Temperature-Controlled Storage Devices
• Temperature Probes: The Benefits of a Solid Thermal Ballast
• Medical-Grade Refrigeration in the Pharmacy: 2020 Trends & Adoption Rates
• USP <800> Refrigerator Frequently Asked Questions Answered

Public access to AHFS Drug Information® (https://www.ahfscdi.com/login) is available for the next 60 days with the username "ahfs@ashp.org" and password "covid-19." ASHP's patient medication information is available at http://www.safemedication.com/.

Access the full Assessment of Evidence for COVID-19-Related Treatments: Updated 4/15/2020 at the link below.

References:

“Assessment of Evidence for COVID-19-Related Treatments:” ASHP-COVID-19, 17 Apr. 2020, www.ashp.org/-/media/assets/pharmacy-practice/resource-centers/Coronavirus/docs/ASHP-COVID-19-Evidence-Table.ashx.